CN101663293B - 作为p2y12拮抗剂的喹啉-甲酰胺衍生物 - Google Patents

作为p2y12拮抗剂的喹啉-甲酰胺衍生物 Download PDF

Info

Publication number
CN101663293B
CN101663293B CN200880013208XA CN200880013208A CN101663293B CN 101663293 B CN101663293 B CN 101663293B CN 200880013208X A CN200880013208X A CN 200880013208XA CN 200880013208 A CN200880013208 A CN 200880013208A CN 101663293 B CN101663293 B CN 101663293B
Authority
CN
China
Prior art keywords
carbonyl
oxo
piperazine
quinoline
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880013208XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101663293A (zh
Inventor
M·纳扎雷
G·策希
M·尤斯特
T·魏斯
G·黑斯勒
J·采奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38462433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101663293(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN101663293A publication Critical patent/CN101663293A/zh
Application granted granted Critical
Publication of CN101663293B publication Critical patent/CN101663293B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200880013208XA 2007-04-23 2008-04-09 作为p2y12拮抗剂的喹啉-甲酰胺衍生物 Expired - Fee Related CN101663293B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07008209 2007-04-23
EP07008209.4 2007-04-23
PCT/EP2008/002790 WO2008128647A1 (en) 2007-04-23 2008-04-09 Quinoline-carboxamide derivatives as p2y12 antagonists

Publications (2)

Publication Number Publication Date
CN101663293A CN101663293A (zh) 2010-03-03
CN101663293B true CN101663293B (zh) 2013-07-31

Family

ID=38462433

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880013208XA Expired - Fee Related CN101663293B (zh) 2007-04-23 2008-04-09 作为p2y12拮抗剂的喹啉-甲酰胺衍生物

Country Status (18)

Country Link
US (1) US8669266B2 (OSRAM)
EP (1) EP2148871A1 (OSRAM)
JP (1) JP5309131B2 (OSRAM)
KR (1) KR20100015886A (OSRAM)
CN (1) CN101663293B (OSRAM)
AR (1) AR066225A1 (OSRAM)
AU (1) AU2008241091B2 (OSRAM)
BR (1) BRPI0810462A2 (OSRAM)
CA (1) CA2684644A1 (OSRAM)
CL (1) CL2008001157A1 (OSRAM)
IL (1) IL201620A (OSRAM)
MX (1) MX2009011089A (OSRAM)
MY (1) MY153427A (OSRAM)
PA (1) PA8777901A1 (OSRAM)
PE (1) PE20090241A1 (OSRAM)
TW (1) TW200848042A (OSRAM)
UY (1) UY31039A1 (OSRAM)
WO (1) WO2008128647A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002070022A2 (en) 2001-02-28 2002-09-12 Uroteq Inc. Method of making anti-microbial polymeric surfaces
US8288371B2 (en) 2007-10-05 2012-10-16 Pharmacopeia, Llc Ortho pyrrolidine, benzyl-substituted heterocycle CCR1 antagonists for autoimmune diseases and inflammation
CN101868469B (zh) 2007-11-29 2014-04-02 埃科特莱茵药品有限公司 膦酸衍生物及其作为p2y12受体拮抗剂
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
RU2401831C2 (ru) * 2008-12-15 2010-10-20 Алла Хем, Ллс Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения
MA33260B1 (fr) 2009-04-08 2012-05-02 Actelion Pharmaceuticals Ltd 6-(3-azabicyclo[3.1.0.]hex-3-yl)-2-phenylpyrimidines
SG175297A1 (en) 2009-04-22 2011-12-29 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists
EP2471792B1 (en) 2009-08-28 2014-04-09 Daiichi Sankyo Company, Limited 3-(biaryloxy) propionic acid derivative
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
EA023998B1 (ru) 2011-03-04 2016-08-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Аминохинолины в качестве ингибиторов киназ
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
WO2013033178A1 (en) 2011-08-30 2013-03-07 University Of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
CN102584852B (zh) * 2011-12-30 2014-08-13 厦门大学 真菌代谢产物桥南霉素及其制备方法和应用
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
EP2725025A1 (fr) * 2012-10-26 2014-04-30 Sanofi Dérives de 1H-indole-3-carboxamide et leurs utilisation comme antagonistes du P2Y12
JP6301374B2 (ja) 2013-02-21 2018-03-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのキナゾリン類
CN104109158A (zh) * 2013-04-16 2014-10-22 上海医药工业研究院 一种纯化利伐沙班的方法
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
DE102015217396B4 (de) 2014-09-11 2018-07-26 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. System, insbesondere System zur Eingabesteuerung für eine Arbeitshilfe
CN106496249B (zh) * 2015-09-07 2019-12-13 江苏恒瑞医药股份有限公司 噁唑并吲哚类衍生物、其制备方法及其在医药上的应用
JP6990228B2 (ja) * 2016-07-14 2022-01-13 ブリストル－マイヤーズ スクイブ カンパニー 二環式ヘテロアリール置換の化合物
PT3515924T (pt) 2016-09-22 2022-03-11 Idorsia Pharmaceuticals Ltd Formas cristalinas
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
CN107648607A (zh) * 2017-09-11 2018-02-02 南昌大学 嘌呤2y12受体拮抗剂在制备糖尿病神经病理损伤疾病药物中的应用
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
WO2023108363A1 (en) * 2021-12-13 2023-06-22 Beijing Honghui Meditech Co., Ltd Pyrimidine-annulated triazole derivatives and their use in platelet aggregation inhibition
CN115429874A (zh) * 2022-09-20 2022-12-06 暨南大学 水蛭素靶向并抑制dpp4治疗糖尿病

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022241A2 (en) * 2005-08-17 2007-02-22 Schering Corporation Novel high affinity quinoline-based kinase ligands

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
CN1149196C (zh) 1998-07-06 2004-05-12 布里斯托尔-迈尔斯斯奎布公司 作为血管紧张肽和内皮肽受体双重拮抗剂的联苯基磺酰胺
WO2000076970A2 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Serine protease inhibitors
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
ES2329881T3 (es) 2001-09-21 2009-12-02 Bristol-Myers Squibb Company Compuestos que contienen lactama y derivados de los mismos como inhibidores del factor xa.
ES2348942T3 (es) * 2002-12-11 2010-12-17 Bayer Schering Pharma Aktiengesellschaft Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor plaquetario de adenosin difosfato.
WO2005009971A1 (ja) 2003-07-24 2005-02-03 Astellas Pharma Inc. キノロン誘導体又はその塩
US7157445B2 (en) * 2004-02-26 2007-01-02 Aventis Pharma S.A. Administration of enoxaparin sodium to patients with severe renal impairment
JP2008094720A (ja) 2005-01-20 2008-04-24 Astellas Pharma Inc キノロン誘導体のプロドラッグ又はその塩
TW200640877A (en) * 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022241A2 (en) * 2005-08-17 2007-02-22 Schering Corporation Novel high affinity quinoline-based kinase ligands

Also Published As

Publication number Publication date
PA8777901A1 (es) 2008-11-19
CN101663293A (zh) 2010-03-03
IL201620A (en) 2013-11-28
MX2009011089A (es) 2009-10-30
TW200848042A (en) 2008-12-16
CA2684644A1 (en) 2008-10-30
AR066225A1 (es) 2009-08-05
PE20090241A1 (es) 2009-04-03
MY153427A (en) 2015-02-13
AU2008241091A1 (en) 2008-10-30
IL201620A0 (en) 2010-05-31
JP5309131B2 (ja) 2013-10-09
CL2008001157A1 (es) 2008-11-03
AU2008241091B2 (en) 2013-05-09
WO2008128647A1 (en) 2008-10-30
JP2010524984A (ja) 2010-07-22
UY31039A1 (es) 2008-11-28
BRPI0810462A2 (pt) 2014-10-14
EP2148871A1 (en) 2010-02-03
KR20100015886A (ko) 2010-02-12
US8669266B2 (en) 2014-03-11
US20100135999A1 (en) 2010-06-03
HK1141803A1 (en) 2010-11-19

Similar Documents

Publication Publication Date Title
CN101663293B (zh) 作为p2y12拮抗剂的喹啉-甲酰胺衍生物
JP6995101B2 (ja) 血漿カリクレイン阻害剤としてのｎ－（（ヘタ）アリールメチル）－ヘテロアリール－カルボキサミド化合物
TWI794297B (zh) 化合物用於製備與第二抗-呼吸道融合性病毒試劑組合使用以治療呼吸道細胞融合病毒感染的藥物之用途及醫藥組合物
CN104395310B (zh) 二环取代尿嘧啶及其用途
JP5560202B2 (ja) Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体
CN101903356B (zh) 4-(4-氰基-2-硫代芳基)二氢嘧啶酮和它们的使用
CN114502158A (zh) Irak降解剂及其用途
TWI551596B (zh) 二醯甘油醯基轉移酶２抑制劑
CN105683175B (zh) 二环抑制剂
JP2020500207A (ja) カルパインモジュレーター及びそれらの治療上の使用
CN105254616A (zh) 取代的n-(2-甲氧基-5-硝基苯基)嘧啶-2-胺化合物及其盐
CN117425646A (zh) 一种膦酰衍生物及其组合物和药学上的应用
CN102971311A (zh) 作为gpr119调节剂的二环杂芳基化合物
EP3981394A1 (en) A sortilin antagonist for use in the prevention or treatment of hearing loss.
WO2018089360A1 (en) Pyrrole amides as alpha v integrin inhibitors
JP2018520201A (ja) Ｔｇｆベーター受容体アンタゴニスト
CN114286820A (zh) 酶抑制剂
CN105873919A (zh) 作为类糜蛋白酶抑制剂的取代的尿嘧啶
CN113348168A (zh) 杂环衍生物
TW201710250A (zh) 經取代之喹喏啉衍生物
JP2016536362A (ja) 置換されているウラシル類及びそれらの使用
HK1141803B (en) Quinoline-carboxamide derivatives as p2y12 antagonists
CN119546590A (zh) 人呼吸道合胞病毒和偏肺病毒的抑制剂
WO2024140850A1 (zh) 一种蛋白酪氨酸激酶抑制剂及其医药用途
CN101296924A (zh) 作为p38激酶抑制剂的吡唑异喹啉脲衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1141803

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1141803

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130731

Termination date: 20160409

CF01 Termination of patent right due to non-payment of annual fee